Pelthos Therapeutics Q1 2026 ZELSUVMI net revenue $10.7M, up 17% QoQ; net loss $10.2M

Pelthos Therapeutics Inc.

2026-Q1 EPS reported -$3.09 revenue$10,906,000

ZELSUVMI net product revenue $10.7M in Q1 2026, up 17% from $9.1M in Q4 2025; units dispensed 7,884 (+25% QoQ).
Net loss of $(10.2)M vs $(21.7)M in Q4 2025; adjusted EBITDA $(8.0)M.
Cash $32.0M as of March 31, 2026; drew $30M from $50M Horizon term loan facility in January 2026.
Sales force expanded to 64 territory managers from 50; April units 3,776; cumulative >20,000 since July 2025 launch.
Planned commercialization of XEPI in early 2027 and XEGLYZE in mid-2027.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pelthos Therapeutics Inc. reported first quarter ended March 31, 2026 results: revenue $10.7 million, net income $(10.2) million.

Period: first quarter ended March 31, 2026
Revenue: $10.7 million
Net income: $(10.2) million
Result: reported results

Exact text from the filing

Therapeutics Announces First Quarter 2026 Financial Results ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Pelthos Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001919246-26-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.